Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

Related Keywords

Australia ,Japan ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,New Zealand ,Chicago ,Illinois ,American ,Matthew Deyoung ,David Wise ,Douglase Onsi ,Oncologist At Perlmutter Cancer Center ,Langone Health ,American Society Of Clinical Oncology ,Beigene Ltd ,Nasdaq ,Prnewswire Leap Therapeutics Inc ,Securities Exchange ,Leap Therapeutics Inc ,Perlmutter Cancer Center ,Clinical Oncology ,Annual Meeting ,Medical Oncologist ,Initial Findings ,Investigator Sponsored Phase ,Clinical Trial ,Investigator Initiated Trial ,Metastatic Castration Resistant Prostate Cancer ,Genitourinary Cancer ,Leap Therapeutics ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Leap Therapeutic ,Annual Report ,Quarterly Reports ,